Results of the international study were presented at the American College of Cardiology's annual meeting in San Francisco on March 10 and published simultaneously online by The New England Journal of Medicine.
Initiated in 2006, the RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) trial involved 2,278 anemic heart failure patients at 453 sites in 33 countries.
Patients were randomly given either darbepoetin alfa or placebo. In the darbepoetin alfa group, 50.7 percent of the patients experienced death from any cause or hospitalization for worsening heart failure. In the placebo group, 49.5 percent of the patients experienced similar clinical outcomes.
The trial was funded by Amgen, the maker of darbepoetin alfa (trade name: Aranesp).
“This landmark study provides answers to caregivers who treat patients with heart failure complicated by anemia,” says James Young, M.D., cardiologist and Chair of the Cleveland Clinic Endocrinology & Metabolism Institute, and co-investigator of the RED-HF trial. “Our findings do not support the use of darbepoetin alfa to treat anemic heart failure patients.”
Anemia, the lack of red blood cells, is a common and serious problem in people who suffer from heart failure. It can lead to worse quality of life, higher rates of hospitalization and death. Treatment options have focused on correcting anemia with the use of intravenous iron or drugs that stimulate red blood cells.
“The benefits of erythropoietin-stimulating agents (ESAs) such as darbepoetin alfa to treat patients with heart failure and anemia have been questioned due to contradictory research findings,” says Karl Swedberg, M.D., Ph.D., a senior professor at the Sweden-based Department of Medicine, Sahlgrenska Academy, University of Gothenburg, and co-investigator of the RED-HF trial.
“Our study results show that the use of darbepoetin alfa to stimulate the production of red blood cells is an ineffective treatment for patients with heart failure and anemia.”
According to the study, researchers found that darbepoetin alfa treatment led to an early and sustained increase in hemoglobin compared with placebo. However, darbepoetin alfa treatment did not reduce the risk of death from any cause or hospitalization from heart failure.
Findings suggest that hemoglobin is a marker of poor prognosis in heart failure, rather than a therapeutic target. There were no new safety findings identified in the study. However, researchers observed an increased risk of thrombosis in the darbepoetin alfa group.
Researchers note that further research is needed to identify treatment options for this patient population.
Link to article: http://www.nejm.org/doi/full/10.1056/NEJMoa1214865Contact:
Annika Koldenius | idw
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
18.01.2017 | Power and Electrical Engineering
18.01.2017 | Materials Sciences
18.01.2017 | Life Sciences